NexGel Calls Celularity Wound Deal “Transformational,” Eyes $35M Revenue and EBITDA Profitability

NexGel (NASDAQ: NXGL) used a shareholder update conference call to discuss the closing of its acquisition of Celularity's Degenerative Wound segment, a move CEO Adam Levy described as "transformational" as the company shifts into what he called a more scalable and diversified medical technology business. Acquisition details and new BioNX Surgical division Levy said the acquired